標(biāo)題: Titlebook: Rheumatic Diseases and Syndromes Induced by Cancer Immunotherapy; A Handbook for Diagn Maria E. Suarez-Almazor,Leonard H. Calabrese Book 20 [打印本頁] 作者: detumescence 時(shí)間: 2025-3-21 17:07
書目名稱Rheumatic Diseases and Syndromes Induced by Cancer Immunotherapy影響因子(影響力)
書目名稱Rheumatic Diseases and Syndromes Induced by Cancer Immunotherapy影響因子(影響力)學(xué)科排名
書目名稱Rheumatic Diseases and Syndromes Induced by Cancer Immunotherapy網(wǎng)絡(luò)公開度
書目名稱Rheumatic Diseases and Syndromes Induced by Cancer Immunotherapy網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Rheumatic Diseases and Syndromes Induced by Cancer Immunotherapy被引頻次
書目名稱Rheumatic Diseases and Syndromes Induced by Cancer Immunotherapy被引頻次學(xué)科排名
書目名稱Rheumatic Diseases and Syndromes Induced by Cancer Immunotherapy年度引用
書目名稱Rheumatic Diseases and Syndromes Induced by Cancer Immunotherapy年度引用學(xué)科排名
書目名稱Rheumatic Diseases and Syndromes Induced by Cancer Immunotherapy讀者反饋
書目名稱Rheumatic Diseases and Syndromes Induced by Cancer Immunotherapy讀者反饋學(xué)科排名
作者: 愉快么 時(shí)間: 2025-3-21 21:59 作者: Headstrong 時(shí)間: 2025-3-22 00:56
Rheumatic Diseases and Syndromes Induced by Cancer Immunotherapy978-3-030-56824-5作者: 使人入神 時(shí)間: 2025-3-22 08:22 作者: Debate 時(shí)間: 2025-3-22 11:08 作者: Expiration 時(shí)間: 2025-3-22 14:45 作者: Haphazard 時(shí)間: 2025-3-22 20:01
Immunopathogenesis of Immune-Related Adverse Events from Cancer Immunotherapyorder to allow the crafting of immunosuppressive/immunomodulatory therapies which will be effective but not compromise the basic antitumoral properties of ICI-based therapies. This chapter reviews current concepts of immunopathogenesis of irAEs and appraises data from in vitro preclinical models and作者: 老人病學(xué) 時(shí)間: 2025-3-22 23:04
Sicca Syndromes condition often develops abruptly and is objectively quite severe. Within the reported cases, we highlight marked clinical heterogeneity with three potential patient subsets: (i) those with . sicca . systemic symptoms, (ii) those with . sicca . systemic symptoms, and (iii) and those with a flare of作者: NAUT 時(shí)間: 2025-3-23 05:00 作者: 匯總 時(shí)間: 2025-3-23 07:56
Book 2021d agents in treating cancer.?It provides an overview of cancer immunology,immunotoxicity, and immunotherapies such as ICI, cytokine-based therapy, and CART. It examines the epidemiology, clinical manifestations, diagnosis, differential diagnosis, and treatment of a variety of rheumatic immune-relate作者: 誰在削木頭 時(shí)間: 2025-3-23 11:20
978-3-030-56823-8Springer Nature Switzerland AG 2021作者: OVERT 時(shí)間: 2025-3-23 16:19 作者: 否認(rèn) 時(shí)間: 2025-3-23 18:06 作者: ALIAS 時(shí)間: 2025-3-24 02:10
Management of Rheumatic Immune-Related Adverse Events (irAEs): General Principlesumor immune response. Glucocorticoids are the first-line agent, but they should be used with caution and limited in both dose and duration if possible. Early referral to rheumatology is the key to addressing the issues in these complex patients. More human trials using DMARDs and biologic treatments are necessary.作者: 小官 時(shí)間: 2025-3-24 02:46
http://image.papertrans.cn/r/image/830082.jpg作者: 撫慰 時(shí)間: 2025-3-24 09:25
https://doi.org/10.1007/978-3-030-56824-5Cancer immunotherapy and rheumatic diseases; Cancer immunotherapy and arthritis; Cancer immunotherapy 作者: 新星 時(shí)間: 2025-3-24 11:43
Immune-Related Adverse Events with Immune Checkpoint Inhibitors: Polymyalgia Rheumatica clinical variant with potentially different pathogenesis, clinical course, and treatment responsiveness. While these patients can present classically, it seems they may also present with atypical clinical features and require higher than expected doses of glucocorticoids or even glucocorticoid-sparing agents.作者: JAMB 時(shí)間: 2025-3-24 18:02 作者: FUSE 時(shí)間: 2025-3-24 19:16
Cancer Immunotherapy in Patients with Preexisting Inflammatory Arthritisexisting rheumatoid arthritis exposed to ICI for melanoma and followed longitudinally is presented in detail to highlight the clinical course and management challenges faced when caring for these patients.作者: V切開 時(shí)間: 2025-3-25 00:25 作者: 牌帶來 時(shí)間: 2025-3-25 06:18
Myositiscle weakness. Muscle biopsies from these patients reveal abundant CD4+ and CD8+ T cells. Importantly, as many as 25% of these patients may have co-existing myasthenia gravis and/or myocarditis. Although optimal treatment strategies remain to be defined, corticosteroids with or without other immunomodulating therapies are often effective.作者: arbovirus 時(shí)間: 2025-3-25 10:34 作者: Generosity 時(shí)間: 2025-3-25 13:54
Benefit-Risk Considerationse therapeutic options, and, most importantly, patient values and preferences. Future research should aim to quantify risks in these special populations to ensure evidence-based decision-making that considers patient trade-offs between quality of life and survival.作者: FLAG 時(shí)間: 2025-3-25 18:12 作者: 抱狗不敢前 時(shí)間: 2025-3-25 23:20
Book 2021bination immunotherapy, the frequency of ICI-induced immune-related adverse events (irAE) is expected to grow substantially. Management of these irAE is challenging as it requires not only consideration of the toxicity but also risk-benefit ratios with respect to the primary cancer. Several rheumati作者: 要塞 時(shí)間: 2025-3-26 01:37 作者: accomplishment 時(shí)間: 2025-3-26 05:49 作者: BLOT 時(shí)間: 2025-3-26 11:16 作者: 現(xiàn)實(shí) 時(shí)間: 2025-3-26 14:40
Immune-Related Adverse Events with Immune Checkpoint Inhibitors: Arthritise effect of ICIs seen by rheumatologists. Inflammatory arthritis can have heterogeneous presentations, but, most commonly, presents as an oligoarthritis or polyarthritis. Tendons may also be involved, and imaging shows a variety of changes, including synovitis, joint effusions, tenosynovitis, enthes作者: ELUC 時(shí)間: 2025-3-26 19:38
Immune-Related Adverse Events with Immune Checkpoint Inhibitors: Polymyalgia Rheumaticatity. It remains unclear whether checkpoint inhibitor-related polymyalgia rheumatica represents the occurrence of a classic rheumatic disease or a new clinical variant with potentially different pathogenesis, clinical course, and treatment responsiveness. While these patients can present classically作者: Excitotoxin 時(shí)間: 2025-3-27 00:17 作者: Aerophagia 時(shí)間: 2025-3-27 04:28 作者: Psa617 時(shí)間: 2025-3-27 06:40
Sarcoidosis reported recently as adverse events following ICIs. When non-caseating granulomas are identified in the absence of other criteria for the diagnosis of systemic sarcoidosis, the term sarcoid-like reaction is commonly used in the cancer setting. Following ICI therapy, sarcoidosis typically presents w作者: Regurgitation 時(shí)間: 2025-3-27 10:40 作者: 開始從未 時(shí)間: 2025-3-27 17:00 作者: antenna 時(shí)間: 2025-3-27 21:47 作者: Exuberance 時(shí)間: 2025-3-28 00:36 作者: Encephalitis 時(shí)間: 2025-3-28 04:35
Cancer Immunotherapy in Patients with Preexisting Rheumatic Diseases: Other Rheumatic Autoimmune Disents with pre-existing rheumatic autoimmune diseases. So far, approximately 50 patients with pre-existing rheumatic conditions other than inflammatory arthritis have been reported being treated with ICIs. There are no dedicated guidelines regarding the management of such patients. Owing to concerns 作者: noxious 時(shí)間: 2025-3-28 09:56
Management of Rheumatic Immune-Related Adverse Events (irAEs): General Principlesumor immune response. Glucocorticoids are the first-line agent, but they should be used with caution and limited in both dose and duration if possible. Early referral to rheumatology is the key to addressing the issues in these complex patients. More human trials using DMARDs and biologic treatments作者: 昏迷狀態(tài) 時(shí)間: 2025-3-28 12:36
Benefit-Risk Considerationsr risk of experiencing adverse events with these agents. Cancer patients with preexisting autoimmune conditions or those who experience rheumatic adverse events with immunotherapy are faced with difficult decisions regarding their treatment. Often, therapeutic gains in survival need to be balanced w作者: BAIL 時(shí)間: 2025-3-28 14:56
Cancer Immunotherapy: Overview of Immune Checkpoint Inhibitorsrelapse. In this chapter, we will discuss seven Food and Drug Administration-approved immune checkpoint inhibitors for the treatment of various malignancies, targeting two main signaling pathways, cytotoxic T-lymphocyte antigen 4 and programmed cell death 1/programmed cell death ligand-1.作者: 簡(jiǎn)潔 時(shí)間: 2025-3-28 20:39 作者: Minuet 時(shí)間: 2025-3-29 00:34 作者: CHAFE 時(shí)間: 2025-3-29 06:37 作者: 使無效 時(shí)間: 2025-3-29 10:32
h mit Herrn Neu kommen ihm die folgenden Gedanken:.Unser Unternehmen ist ja letztlich wie eine Pyramide aufgebaut. Das Management sitzt ?oben“. Obwohl unsere LaKu-Bau GmbH gar nicht sehr gro? ist, bekommen wir von den Gesch?ften und Problemen, die ?unten“, also auf der Ebene der Gruppenleiter und Sa作者: nuclear-tests 時(shí)間: 2025-3-29 13:25
Rethinking Cultural Probes in Community Research and Design as Ethnographic Practiceresources, and agency meet to solve wicked problems (Rittel and Webber, Policy Sciences, 4, 155–169, 1973). In this chapter, we seek to explore the traces that researchers and community members leave behind as indexical forms of representation. Contemporary perspectives urge a critical examination o作者: 膽大 時(shí)間: 2025-3-29 18:20 作者: Horizon 時(shí)間: 2025-3-29 20:13 作者: 技術(shù) 時(shí)間: 2025-3-30 02:10 作者: inhibit 時(shí)間: 2025-3-30 04:38
https://doi.org/10.1007/978-3-031-25113-9ies accompanying diabetes may include retinopathy, cardiovascular disease, peripheral vascular disease and congestive heart failure, which may result in decreased usual activity and limitations in activities of daily living such as shopping for food and ability to read labels and menus. Rates of dep作者: Anonymous 時(shí)間: 2025-3-30 10:49 作者: botany 時(shí)間: 2025-3-30 15:13
A New Information Security Model in Smart Gridrt grid of the close coupling six areas of smart grid generation, transmission, distribution, substation, power, scheduling, and achieving a fully support the strong ai power grid construction and information security control, controllability and under control.作者: COUCH 時(shí)間: 2025-3-30 19:04 作者: insecticide 時(shí)間: 2025-3-30 22:07
Günther Harisch,Michael Kretschmersis. In 2009, the UN Secretary General in a report on the climate change security nexus referred to climate change as a ‘threat multiplier’ prevailing in the security debate and to climate change as a ‘threat minimizer’ pointing to proactive transformative policies towards sustainability. This chapt作者: dagger 時(shí)間: 2025-3-31 02:53
Book 20143rd editiontenz gef?hrdet. Die Prozessgestaltung wird jedoch in vielen Unternehmen zu wenig monet?r bewertet und betriebswirtschaftlich hinterfragt. Es gilt, diese Finanzstr?me – von der Kreditwürdigkeitsprüfung bis zum Zahlungseingang – zu optimieren und den Cash-to-Cash-Cycle zu beschleunigen. Im Rahmen des 作者: sparse 時(shí)間: 2025-3-31 06:50
Information Superiority,-to-machine. Traditionally, these platform- centric computing applications offer vertical benefits that fulfill the functional requirements of a particular company within an enterprise. One of the most vibrant and revolutionary subjects in the area of business performance management today is the new
